|
A Multicenter, prospective, non-interventional study to assess Adherence to treatment for patIeNts with Relapsing Multiple Sclerosis (RMS) who are prescribed subcutaneous (sc) interferon beta-1a
|
Ongoing
|
Interferon Beta-1 a (Rebif)
|
4
|
MS200136_0
|
King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh), King Fahad University Hospital (Al-Khobar), King Faisal Specialist Hospital and Research Center (Jeddah)
|
|
"CAIN457A3404-REALIAA non-interventional, prospective 12-months study to characterize the REAL-life effectiveness and treatment patterns of SecukInumab and current standard of care inpatient with chronic plaque psoriAsis eligible for systemic treatment in the Asia-Pacific and Middle East regions"
|
Ongoing
|
Cosyntex
|
4
|
IN457A3404
|
King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah)
|
|
Does the Addition of Proton Pump Inhibitors to Continuous Enteral Feeding Provide Added Protection Against Upper GI Bleeding in Acutely Ill Patients
|
Ongoing
|
Esmoprozol
|
4
|
RC15/079
|
King Abdulaziz Medical City NG (Riyadh)
|
|
Real World retrospective study of effectiveness and safety of Gilenya (FINgOlimod) in relapsing remitting Multiple Sclerosis in the Middle East and North Africa (FINOMENA)
|
Ongoing
|
Fingolimod
|
4
|
TY720DAE01
|
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah), King Abdulaziz Hospital Oncology Center, King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), Hira Hospital (Makkah), King Fahad Specialist Hospital (Dammam), Dr. Erfan & Bagedo General Hospital (Jeddah)
|
|
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
|
Ongoing
|
ofatumumab
|
3
|
COMB157G2301
|
King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease
|
Ongoing
|
ombitasvir \ paritaprevir \ ritonavir
|
3
|
Version 1.3.1
|
King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah)
|
|
"Open-label, multicenter, single arm, phase II study assessing treatment patient preference for new deferasirox formulation (film-coated tablet) compared to the reference deferasirox dispersible tablet formulation"
|
Ongoing
|
deferasirox
|
2
|
CICL670FIC05
|
King Abdulaziz University Hospital (Jeddah), Hereditary Blood Disease Center (al ahsa), King Abdulaziz Medical City NG (Riyadh)
|
|
International, randomized, open label study to compare the safety and efficacy of lixisenatide vs sulfonylurea on top of basal insulin treatment in Type 2 Diabetes Mellitus subjects who elect to fast during Ramadan
|
Terminated
|
Lixisenatide
|
3
|
LPS14410
|
King Khalid University Hospital (Riyadh)
|
|
A Phase II Study to examine the efficacy and safety of a new drug called Sevuparin on resolution of painful vaso-occlusive crisis in patients with sickle-cell disease.
|
Ongoing
|
Sevuparin
|
2
|
TVOC01
|
King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh), Qatif Central Hospital
|
|
Multicenter Inetrnational neoadjuvant randomized double-blind trial comparing fulvestrant to a combination of fulvestrant and palcociclib in patients with operable luminal breast cancer responding to fulvestrant
|
Ongoing
|
palbociclib fulvestrant
|
3
|
ICRG 1201
|
King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah)
|
